Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Post by aldo451on Dec 04, 2020 1:00pm
133 Views
Post# 32037917

Liminal BioSciences Announces Upcoming Presentations for Ryp

Liminal BioSciences Announces Upcoming Presentations for RypInteresting to read about Successful Pregnancy in A Patient, this is new to me!

Here are the links if interested:

https://ash.confex.com/ash/2020/webprogram/Paper135847.html
https://ash.confex.com/ash/2020/webprogram/Paper137177.html

Poster Presentations

Successful Pregnancy in A Patient with Infertility Due to Congenital Plasminogen Deficiency Treated with Intravenous Plasminogen (Human) Replacement Therapy
Abstract Number: 2703
Session: 322 Disorders of Coagulation: Poster III
Date & Time: Monday 7 December 2020

Acute Airway Obstruction in 4 Pediatric Patients with Congenital Plasminogen Deficiency (C-PLGD) Treated with Intravenous Plasminogen (Human) Replacement Therapy Under an Expanded Access Protocol
Abstract Number: 1799
Session: 322 Disorders of Coagulation: Poster II
Date & Time: Sunday 6 December 2020
<< Previous
Bullboard Posts
Next >>